Focus: Design Therapeutics is a public biotech company focused on drugs targeting nucleotide-repeat expansion disorders, operating from Carlsbad, CA with 201-500 employees. The company maintains a diverse pipeline across oncology, neurology, infectious diseases, cardiovascular, and respiratory indications.
Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Design Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Design Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Design Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Design Therapeutics Stock Price Forecast. Should You Buy DSGN? - StockInvest.us
Design Therapeutics Stock Price Forecast. Should You Buy DSGN? StockInvest.us
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake - Stock Titan
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake Stock Titan
Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares - Stock Titan
Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares Stock Titan
Design Therapeutics (NASDAQ: DSGN) highlights FA data alongside Q2 loss - Stock Titan
Design Therapeutics (NASDAQ: DSGN) highlights FA data alongside Q2 loss Stock Titan
Design Therapeutics, Inc. 2Q 2026: Net loss $(20,165)K, EPS $(0.32) — 10-Q Summary - TradingView
Design Therapeutics, Inc. 2Q 2026: Net loss $(20,165)K, EPS $(0.32) — 10-Q Summary TradingView
Design Therapeutics (DSGN) Edges Higher as Stock Tests Key Resistance Level - Gap and Go - vinanet.vn
Design Therapeutics (DSGN) Edges Higher as Stock Tests Key Resistance Level - Gap and Go vinanet.vn
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo